Class / Patent application number | Description | Number of patent applications / Date published |
514059000 | Dextran or derivative | 32 |
20080221066 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH KILLING EFFECT ON TUMOR CELLS - The present invention is related to a modified hydroxypolymer conjugates preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate and a method for killing cancer cells and treating tumors is also disclosed. The invention is also related to a method for killing tumor cells and treating tumors by administering an effective amount of the modified hydroxypolymer conjugate. | 09-11-2008 |
20080234226 | Use Of Iron(III) Complex Compounds For The Preparation Of A Medicament For Oral Treatment Of Iron Deficiency States In Patients With Chronic Inflammatory Bowel Disease - The use of iron(III) complex compounds with carbohydrates or derivatives thereof for the preparation of a medicament for oral treatment of iron deficiency states in patients with chronic inflammatory bowel disease, in particular Crohn's disease and colitis ulcerosa, is disclosed. | 09-25-2008 |
20080234227 | Dextran functionalized by hydrophobic amino acids - The invention relates to a dextran functionalized by at least one hydrophobic alpha-amino acid radical, said alpha-amino acid being grafted or bonded to the dextran by a bonding arm and a functional group. A hydrophobic amino acid radical is understood as being the product of coupling between the amine of the amino acid and an acid carried by the bonding arm, said dextran being amphiphilic at neutral pH. In an embodiment, the hydrophobic amino acid is selected from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide, 2-indole ethyl-amine and their alkaline cation salts. The present invention relates also to a pharmaceutical composition comprising one of the dextrans according to the invention. | 09-25-2008 |
20090029942 | ADMINISTRATION OF COPPER TO AN ANIMAL - The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer. | 01-29-2009 |
20090215722 | Inhibition of Antigen Presentation with Poorly Catabolized Polymers - Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal. | 08-27-2009 |
20100087393 | METHODS AND COMPOSITIONS OF INHIBITING COMPLEMENT AND CELLULAR ACTIVATION WITH DEXTRAN SULFATE - A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product. | 04-08-2010 |
20100113389 | METHOD OF TREATING GRAFT-REJECTION USING DEXTRAN SULFATE - The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible. | 05-06-2010 |
20100331279 | Inhibition of Antigen Presentation with Poorly Catabolized Polymers - Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal. | 12-30-2010 |
20110118207 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH BONE SEEKING AND TUMOR KILLING MOIETIES - The present invention is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also disclosed. | 05-19-2011 |
20110144054 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents - Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo. | 06-16-2011 |
20110195928 | Administration of Copper to an Animal - The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer. | 08-11-2011 |
20120040928 | METHODS AND COMPOSITIONS FOR INHIBITING CELLULAR PROLIFERATION AND SURGICAL ADHESION - A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammal | 02-16-2012 |
20120094955 | METHOD OF DISSOLVING AN OXIDIZED POLYSACCHARIDE IN AN AQUEOUS SOLUTION - A method of dissolving an oxidized polysaccharide in an aqueous solution using an oligomer additive is described. The resulting aqueous solution of the oxidized polysaccharide may be used in combination with an aqueous solution comprising an amine-containing component to prepare hydrogel tissue adhesives and sealants for medical and veterinary applications, such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions. | 04-19-2012 |
20130035309 | OPHTHALMIC SEALANT COMPOSITION AND METHOD FOR USE - A polymeric hydrogel sealant specifically formulated to seal ophthalmic wounds is provided. The sealant is formed by mixing two aqueous solutions. The first aqueous solution comprises an oxidized dextran having a specific average molecular weight range and oxidation level and the second aqueous solution comprises a 4-arm polyethylene glycol having two primary amine groups at the end of substantially every arm. A kit and method for sealing an ophthalmic wound using the hydrogel sealant is also provided. | 02-07-2013 |
20130079301 | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion - An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO | 03-28-2013 |
20130261080 | HYDROGEL TISSUE ADHESIVE FOR MEDICAL USE - A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery. | 10-03-2013 |
20130274225 | METHOD FOR MAKING A POLYSACCHARIDE DIALDEHYDE HAVING HIGH PURITY - A method for making polysaccharide dialdehydes is disclosed, which uses a combination of precipitation and separation steps to purify the polysaccharide dialdehyde formed by oxidation of a polysaccharide with periodate. The method is simple, rapid, and provides a polysaccharide dialdehyde having very low levels of iodine-containing species and a low ash content. The polysaccharide dialdehyde is particularly suitable for preparing hydrogel adhesives for medical applications. | 10-17-2013 |
20130316977 | PRIMING SOLUTIONS FOR CARDIOPULMONARY BYPASS - The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus. | 11-28-2013 |
20140005142 | METHOD OF STABLY TREATING INCONTINENCE USING A BULKING AGENT | 01-02-2014 |
20140045786 | Hypertonic Dextran Solution and Methods of Treating and Preventing Recurrent Corneal Erosion - An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO | 02-13-2014 |
20140045787 | Hypertonic Dextran Solution and Methods of Treating and Preventing Recurrent Corneal Erosion - An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO | 02-13-2014 |
20140045788 | METHOD OF STABLY TREATING INCONTINENCE USING A BULKING AGENT - The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration. | 02-13-2014 |
20140094435 | Use of Dextran Sulfate - A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml. | 04-03-2014 |
20140100190 | USE OF LIPID CONJUGATES IN CYSTIC FIBROSIS AND APPLICATIONS THEREOF - This invention provides for the use of compounds represented by the structure of the general formula (A): | 04-10-2014 |
20140135285 | DEVICES AND METHODS FOR INHIBITING ADHESION FORMATION - Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment. In one embodiment, an implantable device is provided for reducing or preventing adhesion formation at a post-operative tissue site in a patient, the implantable device including a biodegradable porous matrix comprising dextran, wherein the implantable device is capable of releasing the dextran over at least 2 days. | 05-15-2014 |
20140135286 | COMPOSITIONS AND METHODS FOR INHIBITING ADHESION FORMATION - Compositions and methods are provided for preparing an adhesion barrier that effectively reduce, prevent or treat adhesions in a patient in need thereof. In one embodiment, a matrix is provided comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. The matrix is configured to release from about 30% to about 90% of the dextran loaded in the matrix within 24 to 48 hours. | 05-15-2014 |
20140142063 | HYDROGEL TISSUE ADHESIVE HAVING DECREASED GELATION TIME AND DECREASED DEGRADATION TIME - A hydrogel tissue adhesive having decreased gelation time and decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide containing aldehyde groups with a water-dispersible, multi-arm amine in the presence of a thiol additive. The thiol additive accelerates the process to form the hydrogel and accelerates the degradation of the hydrogel formed. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery. | 05-22-2014 |
20140206644 | METHODS AND COMPOSITIONS FOR INHIBITING CELLULAR PROLIFERATION AND SURGICAL ADHESION - The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention. Thus, the invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. The anionic component for use in the invention includes all proteoglycans, glyosaminoglycans, pentosan polysulfates, alginates and the anti-platelet agent can be on synthetic, peptides, proteins or antibodies. A preferred embodiment of the invention is one in which the conjugate compound dextran sulfate is paired with pentosan polysulfate. In a more preferred specific embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight of the final bound compound is approximately 40,000 to 500,000 Daltons. | 07-24-2014 |
20140315855 | Antidandruff Agent Sulfated Polysaccharides - The invention relates to the cosmetic use of a sulfated polysaccharide chosen from: dextran sulfate and sulfated polysaccharides derived from the red alga | 10-23-2014 |
20150105346 | DEXTRAN-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum. | 04-16-2015 |
20160067275 | CO-CROSSLINKED PHOSPHATED NATIVE AND/OR FUNCTIONALIZED POLYSACCHARIDE-BASED HYDOGEL - Phosphorylated hydrogels obtained by co-cross-linking hyaluronic acid with dextran, a process for preparing same, and a use of the hydrogel for the encapsulation and extended release of active principles as well as cells for use in regenerative human and veterinary medicine. | 03-10-2016 |
20160122445 | ENZYMATICALLY POLYMERIZED GELLING DEXTRANS - Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed. | 05-05-2016 |